Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain

Spinal Cord Injuries Clinical Trial

Official title:

Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01479556
• Other study ID #: HNP-02-2011
• Secondary ID: 2011-000915-14
• Status: Not yet recruiting
• Phase: Phase 4
• First received: November 17, 2011
• Last updated: November 22, 2011
• Start date: December 2011
• Est. completion date: October 2014

Study information

• Verified date: November 2011
• Source: Hospital Nacional de Parapléjicos de Toledo
• Contact: Julian Taylor Green
• Phone: (34) 925 247 700
• Email: jscott[@]sescam.org
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

This study is a phase IV clinical trial with the objective of evaluating whether pain relief associated with pregabalin for at-level non-evoked and evoked neuropathic pain is more efficient during the early rather than late subacute phase of spinal cord injury.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 82
• Est. completion date: October 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Comprehension of clinical trial and signed informed consent before initiation.

• Male or female adults, age 18 to 70.

• Clinical history of neuropathic pain secondary to SCI

• Patients with an AIS of A, B, C or D according to the American Spinal Cord Injury Association (ASIA) Impairment Scale.

• Persistent neuropathic pain from 1 month up to 6 months after spinal cord injury.

• Non-evoked at-level pain with = 2 intensity measured with the numerical rating scale (0-10).

• Non-evoked/evoked at-level pain corresponding to the area of sensory alteration, and within the three dermatomes below the neurological level of the spinal cord injury.

• Formal acceptance of disponibility for all programmed clinical trial visits and other protocol requisites.

• Females of child bearing age must demonstrate a negative pregnancy test (performed on screening and subsequent follow up visits) and use a reliable birth control method including abstinence of sexual activity throughout the duration of the study and for at last 28 days after termination of the clinical trial.

Exclusion Criteria:

• Previous or actual use of gabapentin.

• Creatinine clearance level <60 ml/min.

• Neuropathic pain unrelated to spinal cord injury.

• Lactose intolerance, Lapp lactase insufficiency or glucose malabsorption

• Platelet count < 100x103/µl.

• White blood cell count <2.5 x103/µl.

• Neutrophil count <1.5 x103/µl.

• Planned surgery during the clinical trial.

• Patients with peripheral neuropathic pain.

• Previous history of malignant melanoma.

• History of malignant tumors, except for in situ uterine cervix carcinoma, in situ basocellular or spinocellular cutaneous carcinomas, superficial bladder tumors (Ta and Tis) with a complete treatment response up to 10 years. Patients with history of lymphoma or breast cancer will be allowed to participate in the trial if a complete treatment response has been observed up to 20 years.

• Chronic or active infection requiring a systemic therapy, chronic kidney infections, chronic lung infections with bronchiectasias, Mycobacterium tuberculosis infection, active Hepatitis B or C. Diagnosis of latent TB confection should be performed according to the local guidelines.

• Severe heart diseases such as unstable angina, cardiopathy during the first 6 months after a myocardial infarction, grade III or IV of the New York Heart Association scale for congestive heart failure.

• Unknown kidney, liver, gastrointestinal, endocrine, lung, hematological, neurological or psychiatric comorbidities.

• Subjects administered with an experimental or non-commercial drug during the 4 weeks prior to the trial.

• Patients participating in other clinical studies.

• Patients that are not competent for completing required tasks (eg. alcohol or drug related problems or psychiatric disorders).

• Subjects unable to be examined with radiological MRI exploration due to contraindications.

• Pregnancy or breastfeeding.

• Any other patient condition that is deemed unsuitable for subject inclusion in the trial according to the research team.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuropathic Pain
• Spinal Cord Injuries

Intervention

Drug:
• Pregabalin
Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
• Placebo
150mg BID p.o.

Locations

Country	Name	City	State
Spain	Hospital Nacional de Parapléjicos de Toledo	Toledo

Sponsors (1)

Lead Sponsor	Collaborator
Julian Taylor Green

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Daily at-level non-evoked pain intensity measured with the numerical rating scale (0-10) expressed as the mean 7-day pain intensity
Secondary	Weekly below-level non-evoked pain intensity measured with the numerical rating scale (0-10)
Secondary	Weekly evaluation of at-level neuropathic pain symptoms using the "Neuropathic Pain Symptoms Inventory" (NPSI)
Secondary	Weekly evaluation of at-level neuropathic pain intensity and interference using the "Brief Pain Inventory" (BPI)
Secondary	Weekly evaluation of the change in at-level non-evoked neuropathic pain using the "Patient Global Impression Change" (PGIC)
Secondary	Weekly evaluation of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)
Secondary	Weekly evaluation of spasm frequency below the spinal cord injury using the Penn questionnaire
Secondary	Measurement of the amplitude of cold and heat sensory evoked potentials (Cz-Fz) studied above (C4) and at-level of the SCI
Secondary	Serum TNF-R1 level
Secondary	Weekly at-level non-evoked pain intensity measured with the numerical rating scale (0-10) 28 days after the termination of the clinical trial
Secondary	Number of Paracetamol tablets used as rescue medication during the week
Secondary	Prevalence and type of adverse events in patients treated with pregabalin
Secondary	Unblinding testing: patient and investigator will be asked for the treatment they think to have received. Reasons for their judgement (efficacy and safety) will also be asked.